Tandem Diabetes Care Reports Strong Q3 Growth
Company Announcements

Tandem Diabetes Care Reports Strong Q3 Growth

Tandem Diabetes Care ( (TNDM) ) has released its Q3 earnings. Here is a breakdown of the information Tandem Diabetes Care presented to its investors.

Tandem Diabetes Care is a global company specializing in insulin delivery and diabetes technology, known for its advanced automated insulin delivery systems, including the Tandem Mobi and t:slim X2 pumps with Control-IQ technology. In its third quarter of 2024, Tandem Diabetes Care reported significant financial growth, with worldwide GAAP sales rising 31 percent to $244 million and non-GAAP sales increasing by 25 percent. The company also saw a notable increase in pump shipments, exceeding 25 percent growth, and achieved positive Adjusted EBITDA and free cash flow. Key financial highlights include GAAP gross profit of $124.7 million and an operating loss of $26.1 million, with net loss reducing to $23.3 million from $33 million the previous year. Tandem Diabetes Care anticipates continued growth with increased sales guidance for 2024, projecting non-GAAP sales between $903 million and $910 million, with a focus on maintaining a 51 percent gross margin. The management remains optimistic about achieving its strategic goals for the year, continuing its mission to enhance the lives of people with diabetes.

Related Articles
TheFlyTandem Diabetes price target raised to $60 from $58 at Barclays
TheFlyTandem Diabetes price target lowered to $40 from $43 at UBS
TheFlyTandem Diabetes price target lowered to $56 from $57 at Canaccord
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App